What is Obesity?
According to the World Health Organization (WHO), overweight and obesity are defined as abnormal or excessive fat accumulation that presents a risk to health. A body mass index (BMI) over 25 is considered overweight, and over 30 is obese.

- In 2019, an estimated 5 million noncommunicable disease (NCD) deaths were caused by higher-than-optimal BMI.
- Rates of overweight and obesity continue to grow in adults and children. From 1990 to 2022, the percentage of children and adolescents aged 5–19 years living with obesity increased four-fold from 2% to 8% globally, while the percentage of adults 18 years of age and older living with obesity more than doubled from 7% to 16%.
- Obesity increases the risk of many diseases including diabetes, heart disease, stroke, and more and reducing fat mass may improve patient outcomes dramatically.
2 in 5
Adults in the U.S. have obesity.
40 to 59
Age of adults where obesity is most prevalent.
Active Clinical Trials
This is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple doses of ARO-INHBE in adult participants with obesity (Part 1), and the safety, tolerability and PD of repeat doses of ARO-INHBE in adult participants with obesity with and without type 2 diabetes mellitus receiving tirzepatide (Part 2). Part 2 will commence after evaluation of safety data from Part 1 multiple-dose cohorts through Day 43. The dose for Part 2 will be based upon evaluation of data from Part 1.

Compassionate Use
Learn more about our compassionate use agreement and eligibility criteria for medicines in our pipeline that are currently in clinical development.

Area of Focus
Discover our areas of expertise and how we’re working to address clinical needs.

Patients & Caregivers
See how we’re advancing science to improve the lives of patients and their loved ones.

Science & Innovation
We’re relentless in our pursuit of altering the course of diseases.